What is the primary difference between FDA Section 361 and Section 351 biologics?

Section 361 biological products (HCT/Ps) are tissue-based products that require minimal manipulation, are intended solely for homologous use, and do not rely on living cell metabolic activity for primary function. Section 351 biologics fail one or more of these criteria and are classified as biological drugs requiring premarket approval (BLA) or an Investigational New Drug (IND) application.

Are exosomes regulated under Section 361 or Section 351?

The FDA considers acellular or isolated extracellular vesicles (exosomes) derived from human cells to be Section 351 biological products. Because they are isolated products intended to alter cellular behavior, they require an approved IND or BLA for commercial distribution and clinical use in human subjects.

How does FDA regulation apply to autologous Platelet-Rich Plasma (PRP)?

Autologous PRP prepared at the point of care is generally regulated as a blood component or via medical device medical processing kits under 21 CFR Part 820 / Section 510(k) cleared centrifuges, rather than as a Section 361 or 351 tissue product, provided no unapproved additives or extensive processing steps are introduced.

What happens if a practice uses an unapproved Section 351 biological product?

Using unapproved Section 351 products can result in FDA Warning Letters, product seizures, state medical board sanctions, loss of clinical malpractice coverage for procedures involving the product, and severe legal liability for practice owners.

What documentation should practice managers request from biologics vendors?

Practice managers should request an active FDA Establishment Registration (Form FDA 3483), evidence of donor communicable disease screening, a lot-specific Certificate of Analysis (CoA), third-party sterility and endotoxin testing, and tissue bank accreditation documentation.

FDA Section 361 vs 351 Compliance for Office Biologics

FDA Section 361 vs 351 compliance for office biologics hinges on whether a human cell or tissue product (HCT/P) meets criteria for minimal manipulation and homologous use under 21 CFR 1271, or requires full premarket approval as a Section 351 biological drug. For clinical providers and practice managers, properly auditing product classification is essential to avoid federal enforcement actions, liability, and inventory disruption. Evaluating vendor regulatory documentation and processing standards ensures your practice sources compliant biologics that meet strict federal guidelines.

Understanding 21 CFR 1271: The Regulatory Framework

Title 21 of the Code of Federal Regulations (CFR) Part 1271 governs human cells, tissues, and cellular and tissue-based products. The FDA established this framework to prevent the introduction, transmission, and spread of communicable diseases while maintaining appropriate oversight based on the level of risk associated with the product and its processing.

In outpatient regenerative practices, confusion often arises when purchasing structural allografts—such as umbilical cord tissue, Wharton's jelly, amniotic fluid, or placental membranes—or autologous blood derivatives. To maintain legal compliance when integrating biologics into clinical workflows, medical directors and practice administrators must understand the exact threshold between lower-risk Section 361 tissue products and higher-risk Section 351 biological drugs.

Section 361 Tissue Products (HCT/Ps)

Section 361 HCT/Ps are regulated solely to prevent communicable disease transmission. They do not require premarket approval (such as a Biologics License Application, or BLA) or an Investigational New Drug (IND) application prior to commercial distribution, provided they meet all requirements under 21 CFR 1271.10(a).

Section 351 Biological Drugs

If an HCT/P fails to meet any single criterion of 21 CFR 1271.10(a), it is automatically classified as a Section 351 product. Section 351 biologics are treated as prescription drugs or biological products. They require preclinical studies, clinical trials under an approved IND, and ultimate BLA licensure from the FDA before they can be legally marketed, sold, or administered commercially.

Section 361 HCT/P Criteria vs. Section 351 Drug Classification

To remain within the Section 361 regulatory pathway, an office biologic must satisfy every item in the following compliance checklist. If a product fails even one test, it falls under Section 351 oversight:

Minimal Manipulation (Structural Tissues): Processing cannot alter the original relevant characteristics of the tissue relating to its utility for reconstruction, repair, or replacement. Micronization, enzymatic digestion, or chemical addition that alters structural properties triggers Section 351 status.
Minimal Manipulation (Cells or Nonstructural Tissues): Processing cannot alter the relevant biological characteristics responsible for the tissue's innate function.
Homologous Use Only: The product must perform the same basic function or functions in the recipient as in the donor. For example, using a structural tissue for cushion, lubrication, or mechanical support in musculoskeletal applications is considered homologous. Using structural tissue to treat systemic, metabolic, neurological, or organ-based diseases is considered non-homologous and requires an IND/BLA under Section 351.
Non-Combination Product: The product cannot be combined with another drug, device, or synthetic agent (with limited exceptions for specified water, crystalloids, or sterilizing agents that do not alter therapeutic claims).
Metabolic Activity and Systemic Effect: For allogeneic tissue, the product must not rely on the metabolic activity of living cells for its primary function, nor can it exert a systemic effect, unless intended for autologous use or use in first- or second-degree blood relatives.

Clinical Considerations: Homologous Use and Processing Integrity

For regenerative medicine doctors and treating clinicians, biological compliance directly impacts clinical protocol design, patient informed consent, and professional liability.

Documenting Homologous Intent

Clinicians must ensure that the clinical rationale for placing an allograft matches its native biological function. For example, applying an amniotic membrane allograft as a protective barrier or structural covering over damaged connective tissue aligns with homologous structural utility. Conversely, administering tissue allografts intravenously or advertising them as disease-modifying therapies for systemic auto-immune or neurodegenerative conditions breaches the homologous use rule. Such claims reclassify the product as a Section 351 drug in the eyes of regulatory authorities.

Processing Methods and Biological Function

Clinicians must review the manufacturer's Certificate of Analysis (CoA) and processing methodologies. Mechanical centrifugation or simple washing generally meets minimal manipulation standards. However, protocols involving enzymatic digestion (such as collagenase isolation of stromal vascular fraction), cell expansion in culture, or chemical alteration disrupt tissue architecture, shifting the product into Section 351 drug territory.

Operational and Financial Risk Management for Practice Administrators

Practice administrators, office managers, and procurement officers face significant administrative, financial, and legal risks when sourcing office biologics. Understanding the regulatory landscape is essential to protecting the practice's operations and financial standing.

Liability and Malpractice Coverage

Most medical professional liability insurance policies specifically exclude coverage for claims arising from the administration of unapproved drugs or investigational products used outside an FDA-sanctioned clinical trial. Administering an allograft that is marketed as a 361 HCT/P but functions legally as an unapproved 351 drug can leave clinicians and the practice entirely exposed to uninsurable malpractice claims.

Vendor Due Diligence and Vendor Audits

Practices cannot rely solely on vendor marketing materials or distributor guarantees regarding regulatory status. Administrators must verify that every tissue manufacturer maintains an active FDA Establishment Registration (FDA Form 3483) and undergoes routine FDA inspections. Reviewing tissue bank accreditations (such as American Association of Tissue Banks, or AATB, accreditation) adds an essential layer of quality assurance.

Inventory and Chain of Custody Management

Section 361 regulations require comprehensive donor screening, communicable disease testing, and strict tracking from donor recovery to final clinical application. Practice procurement teams must maintain detailed logs linking product lot numbers to specific patient medical records. In the event of an FDA recall or safety warning, the practice must be capable of tracing and reporting every affected unit immediately.

What This Means for Your Practice

Navigating FDA Section 361 vs 351 compliance requires clear operational protocols and disciplined procurement routines. Practice leadership should implement the following steps immediately:

Audit Current Biologics Inventory: Review all tissue allografts, amniotic products, exosomes, and cellular products currently in stock. Ensure that manufacturer documentation clearly demonstrates Section 361 compliance or an active IND/BLA clearance.
Review Marketing and Patient Education Materials: Inspect practice websites, social media content, and consultation forms. Remove any language suggesting that 361 allografts cure, treat, or reverse systemic diseases, organ dysfunction, or chronic systemic conditions.
Standardize Procurement Vetting: Mandate that all prospective tissue suppliers provide an up-to-date FDA registration number, a current Certificate of Analysis, donor screening protocols, and a clear legal opinion confirming Section 361 status.
Train Clinical and Administrative Staff: Conduct bi-annual training covering chain-of-custody documentation, temperature storage logs, lot tracking, and proper clinical chart note entry for structural allografts.
Establish Vendor Compliance Files: Maintain a central compliance folder (digital or physical) containing verified vendor regulatory files, tissue bank licenses, and emergency contact protocols for recall management.

Partnering with Compliant Biologics Distributors

Selecting a distributor that prioritizes regulatory adherence, quality control, and clinical transparency is critical to mitigating operational risk. Working with established supply partners ensures that every allograft and biologic supplied meets stringent regulatory standards.

Learn more about our strict regulatory standards and tissue sourcing standards by reviewing our about page, or consult our regulatory guidelines in the FAQ section. To discuss regulatory compliance, product documentation, or procurement protocols for your clinical practice, contact our clinical team today via our contact page.